Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.

about

Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain.No Increased Risk of Fracture in Patients Receiving Antimuscarinics for Overactive Bladder Syndrome: A Retrospective Cohort Study.

P2860

Q37300812-91489DF6-62B5-42DB-801F-CD92D52609F3 Q47189750-6B90A5E7-AB80-4AFB-8C58-0E4ECFD422B9

P2860

Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.

Item

http://www.wikidata.org/entity/Q38190923

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Cost effectiveness of fesotero ...... ntinence in Spain and Finland.

@en

type

Item

label

Cost effectiveness of fesotero ...... ntinence in Spain and Finland.

@en

prefLabel

Cost effectiveness of fesotero ...... ntinence in Spain and Finland.

@en

P1476

Cost effectiveness of fesotero ...... ntinence in Spain and Finland.

@en

P2093

Antti Valpas

http://www.w3.org/2001/XMLSchema#string

Javier Rejas

http://www.w3.org/2001/XMLSchema#string

Kari Linden

http://www.w3.org/2001/XMLSchema#string

Marion Kvasz

http://www.w3.org/2001/XMLSchema#string

Sonya J Snedecor

http://www.w3.org/2001/XMLSchema#string

P2860

Is the prevalence of overactive bladder overestimated? A population-based study in Finland

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.

Using cost effectiveness information.

Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry.

High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions.

Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.

The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.

The medical treatment of overactive bladder, including current and future treatments.

P304

297-307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40261-014-0178-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Javier C. Angulo

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24567280

http://www.w3.org/2001/XMLSchema#string

P921

Finland

Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.

about

P2860

P2860

Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921